Loading…
Spero Therapeutics, Inc. is projected to rise to $1.46 by 2027, a +25% move from its current price of $1.17. SPRO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.12 | $1.17 | $1.23 | -0.05% |
| Aug 6 | $1.09 | $1.17 | $1.25 | -0.09% |
| Aug 7 | $1.08 | $1.17 | $1.27 | -0.14% |
| Aug 8 | $1.06 | $1.17 | $1.28 | -0.19% |
| Aug 9 | $1.05 | $1.17 | $1.30 | -0.24% |
| Aug 10 | $1.04 | $1.17 | $1.31 | -0.28% |
| Aug 11 | $1.03 | $1.17 | $1.32 | -0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.03 | $1.17 | $1.32 | -0.33% |
| Week 2 | $0.9729 | $1.16 | $1.39 | -0.66% |
| Week 3 | $0.9317 | $1.16 | $1.44 | -0.99% |
| Week 4 | $0.8979 | $1.15 | $1.48 | -1.31% |
| Week 5 | $0.8687 | $1.15 | $1.52 | -1.64% |
| Week 6 | $0.8429 | $1.15 | $1.56 | -1.96% |
| Week 7 | $0.8196 | $1.14 | $1.59 | -2.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Its product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. The company has license agreements with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries.
Spero Therapeutics was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SPRO is the stock ticker for Spero Therapeutics, Inc. The current price is $1.16 and the market cap is $67.17M, with a rank of 4334.
The near-term technical picture shows NEUTRAL sentiment, with RSI14 at 20 and nearby moving averages near the price: SMA50 at $2.35 and SMA200 at $2.39. The stock’s stated support is $1.16 and resistance is $2.91, framing the immediate risk/reward.
The 30-day price range spans from $0.7994 to $1.68, indicating recent consolidation within a tight band. Annualized volatility is listed at 100%.$
A major floor 64.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.9% away) — a key level to hold.
The nearest ceiling, 94.9% above — a clean break opens room to run.
A major ceiling 154.7% above — clearing it would confirm fresh momentum.
Key SPRO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SPRO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.19 | Sell | $1.20 | Sell |
| MA 10 | $1.24 | Sell | $1.30 | Sell |
| MA 20 | $1.59 | Sell | $1.53 | Sell |
| MA 50 | $2.18 | Sell | $1.95 | Sell |
| MA 100 | $2.38 | Sell | $2.18 | Sell |
| MA 200 | $2.36 | Sell | $2.22 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 21.76 | Buy |
| Stoch RSI (14) | 29.16 | Neutral |
| CCI (20) | -78.59 | Neutral |
| Williams %R (14) | -98.15 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -31.18 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 1.85 | Buy |
| TRIX (15) | -2.05 | Sell |
| Awesome (5,34) | -0.71 | Sell |
| Ultimate (7,14,28) | 19.72 | Buy |
| Momentum (10) | -0.41 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 1.17 | Sell |
| ADX (14) | 42.06 | Sell |
| ATR (14) | 0.07 | Info |
The near-term technical picture remains NEUTRAL, with RSI14 at 20.
SMA50 is $2.35 and SMA200 is $2.39, placing the current price slightly below short- and long-term moving averages. Support is at $1.16 and resistance at $2.91, defining a testable boundary for the next weeks.
The 30-day range runs from $0.7994 to $1.68, outlining the recent trading corridor for SPRO.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.16 | $1.17 | $1.38 | 0% | Neutral | |
| $1.09 | $1.46 | $2.12 | +25% | Bullish | |
| $1.08 | $1.53 | $2.35 | +31% | Bullish | |
| $0.9588 | $1.42 | $2.29 | +22% | Bullish | |
| $0.8582 | $1.33 | $2.21 | +13% | Neutral | |
| $0.784 | $1.26 | $2.17 | +7% | Neutral | |
| $0.9355 | $1.55 | $2.76 | +33% | Bullish | |
| $1.09 | $1.87 | $3.41 | +60% | Bullish | |
| $1.08 | $1.92 | $3.57 | +64% | Bullish | |
| $1.03 | $1.90 | $3.61 | +62% | Bullish | |
| $1.35 | $2.88 | $5.99 | +146% | Bullish | |
| $1.69 | $3.76 | $8.66 | +222% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.16 | $1.17 | $1.39 | +0.00% |
| September 2026 | $0.899 | $1.09 | $1.37 | -7.15% |
| October 2026 | $0.9161 | $1.12 | $1.43 | +3.15% |
| November 2026 | $0.9041 | $1.12 | $1.45 | -0.32% |
| December 2026 | $0.8387 | $1.05 | $1.38 | -6.38% |
Click any year to see its month-by-month SPRO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SPRO is projected to trade between $1.16 and $1.38, averaging $1.17 — a potential gain of 0% from today's $1.17. A consolidation phase looks the most probable path here.
Spero Therapeutics, Inc.'s 2027 outlook centres on $1.46, within a $1.09 to $2.12 range. That is up +25% on the projected 2026 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2028, SPRO could reach as high as $2.35, with a base case around $1.53 and support toward $1.08 — roughly +31% from $1.17. Buyers look set to stay in control over this stretch.
Expect SPRO to range from $0.9588 to $2.29 through 2029. The $1.42 average target implies a +22% move from current prices. That is -7% versus the projected 2028 average. Momentum favours further upside here.
The SPRO price prediction for 2030 points to an average of $1.33 (low $0.8582, high $2.21) — a potential gain of +13% on today's $1.17. A consolidation phase looks the most probable path here.
In 2031, SPRO is projected to trade between $0.784 and $2.17, averaging $1.26 — a potential gain of +7% from today's $1.17. That is -5% versus the projected 2030 average. Price action looks broadly range-bound.
Spero Therapeutics, Inc.'s 2032 outlook centres on $1.55, within a $0.9355 to $2.76 range. That is up +24% on the projected 2031 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SPRO could reach as high as $3.41, with a base case around $1.87 and support toward $1.09 — roughly +60% from $1.17. Momentum favours further upside here.
Expect SPRO to range from $1.08 to $3.57 through 2034. The $1.92 average target implies a +64% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The SPRO price prediction for 2035 points to an average of $1.90 (low $1.03, high $3.61) — a potential gain of +62% on today's $1.17. Momentum favours further upside here.
In 2040, SPRO is projected to trade between $1.35 and $5.99, averaging $2.88 — a potential gain of +146% from today's $1.17. That is up +52% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Spero Therapeutics, Inc.'s 2050 outlook centres on $3.76, within a $1.69 to $8.66 range. That is up +31% on the projected 2040 average. That marks a +222% change versus current levels. Momentum favours further upside here.
Investing $1,000 in SPRO today (≈ 854.700855 SPRO) could be worth
$3,216.3
+$2,216.3 (+222%) by 2050 · US Dollar
Based on the average projected SPRO price of $3.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SPROwould be worth at today's price.
$1,000 invested in SPRO on Jul 31, 2025 (≈ 431.034495 SPRO) would be worth
$504.31
-$495.69 (-49.6%) today · 0.50× · US Dollar
Based on a SPRO entry price of $2.32 vs. today's $1.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.19 | $983.19 | -1.7% |
| 1 month ago | $2.22 | $527.03 | -47.3% |
| 3 months ago | $2.48 | $471.77 | -52.8% |
| 6 months ago | $2.23 | $524.66 | -47.5% |
| 1 year ago | $2.32 | $504.31 | -49.6% |
| All time (5.0y) ago | $14.18 | $82.51 | -91.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SPRO forecast.
Our base-case forecast reaches $2.30 around 2040.
Implied market cap at $2.30: $133.17M
The multi-year forecast shows a path of gradual price movement with notable upside in later years. In 2027 the average forecast is $1.53, up from a 2026 baseline of $1.16, with a max of $2.27 and a min of $1.11 and a 31.6% ROI; sentiment is BULLISH for that year. In 2028 the average is $1.55 with a max of $2.45, a min of $1.06 and a 33.3% ROI, also BULLISH.
In 2029 the average is $1.39 (min $0.8998, max $2.31) and the ROI is 19.5% with NEUTRAL sentiment. For 2030 the forecast shows an average of $1.32 (min $0.8184, max $2.29) and a 13.9% ROI, with NEUTRAL sentiment.
The years 2031 through 2035 show mixed but generally bullish momentum, leading to 2032 avg $1.48 (ROI 28) and 2033 avg $1.89 (ROI 62.6), 2034 avg $1.87 (ROI 60.9), and 2035 avg $1.86 (ROI 60.1), all with BULLISH or neutral tilting higher. By 2040 the forecast stands at an average of $2.82 (min $1.27, max $6.19) with a 143.2% ROI and a BULLISH sentiment. By 2050 the average is $3.45 (min $1.55, max $7.93) and the ROI reaches 197.3% with a BULLISH stance.
These figures are estimates and not guarantees, and they should be considered in the context of the asset’s early-stage clinical profile and market dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.32 with a min of $0.8184 and a max of $2.29; ROI is 13.9% and sentiment NEUTRAL.
Yes. The 2033 forecast lists an average of $1.89 with a max of $3.59, a min of $1.03 and a ROI of 62.6%, with a BULLISH sentiment.
Current price is $1.16 and market cap is $67.17M.
The forecast shows multiple years with positive ROI, including 2027 (31.6%), 2028 (33.3%), 2032 (28%), 2033 (62.6%), 2034 (60.9%), 2035 (60.1%), 2040 (143.2%), and 2050 (197.3%), but some years show smaller gains or flat performance; these are estimates, not guarantees.
The 2040 forecast lists an average of $2.82 (min $1.27, max $6.19) with ROI 143.2% and sentiment BULLISH.
Spero Therapeutics, Inc. Community Discussion
0Share your Spero Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.